NeuroStar Celebrates Milestone in Suicide Prevention Efforts
NeuroStar Celebrates Milestone in Suicide Prevention Efforts
MALVERN, Pa. – Neuronetics, Inc. (NASDAQ: STIM), a dedicated medical technology company, focuses on enhancing the lives of patients suffering from neurohealth disorders. In honor of Suicide Prevention Month, the company is proud to highlight the powerful narratives shared through the NeuroStar Voices Portal. This platform, launched last year, serves as an essential space for individuals to express their experiences with depression and the life-changing effects of NeuroStar Advanced Therapy.
Reaching a Transformative Milestone
Neuronetics is thrilled to announce that it has reached a significant milestone, achieving halfway toward its ambitious goal of saving 3,325 lives through this transformative therapy. Since its inception, NeuroStar has successfully treated over 88,533 patients, resulting in an estimated 1,771 lives saved. This accomplishment is part of a broader five-year plan aimed at treating 166,240 individuals with NeuroStar TMS, showcasing remarkable progress since its FDA clearance in 2008. The number of patients treated in recent years symbolizes a tremendous leap in the ongoing effort to combat depression.
The Impact of NeuroStar Advanced Therapy
“Setting the goal of saving 3,325 lives was not simply a target—it was a compassionate promise to provide hope to those enduring the struggles of mental health,” stated Keith J. Sullivan, the President and CEO of Neuronetics, Inc. “Reaching this halfway point highlights that every life saved represents the courage of those battling depression and the substantial impact that NeuroStar has on their journey to recovery. The heartfelt stories shared via the NeuroStar Voices Portal serve to personalize these achievements, emphasizing the life-altering benefits of our therapy and the renewed hope it provides to countless individuals and their families.”
Powerful Testimonials from Patients
The NeuroStar Voices Portal showcases powerful testimonials from patients who have experienced life-saving changes as a result of NeuroStar TMS therapy. Here are a few inspiring stories:
- "My life has completely changed since NeuroStar TMS. I tell everybody all the time that it did not just change my life, but it saved my life." – Kayla
- "NeuroStar TMS was probably the best thing that could have happened. I feel so much freer without that heaviness of depression. There's light now." – Curry
- "I want people with depression to know that THEY are worth the time commitment, the effort, and the healing NeuroStar TMS will bring to help them return to a productive, happy life!" – Kat
The Importance of Continued Mental Health Innovation
Recent statistics from the Centers for Disease Control and Prevention indicate a worrying trend, with suicide deaths reaching near 50,000 in a single year, stressing a profound need for effective mental health treatments. This critically underlines the urgency for continued innovation and dedicated efforts in mental health care, showcasing how NeuroStar plays an essential role in providing support and hope to individuals in distress.
About Neuronetics and NeuroStar Advanced Therapy
Neuronetics, Inc. believes in the fundamental importance of mental health alongside physical health. As a global leader in neuroscience, the company is transforming expectations for both patients and physicians through its NeuroStar Advanced Therapy for Mental Health. This non-drug, non-invasive treatment significantly improves the quality of life for those suffering from neurohealth disorders when traditional medications fall short. Specifically, NeuroStar is indicated for treating depressive episodes and alleviating anxiety symptoms for individuals affected by Major Depressive Disorder (MDD).
For more information on the incredible impact of NeuroStar TMS Therapy or for safety and prescribing details, visit www.neurostar.com.
Frequently Asked Questions
What is NeuroStar Advanced Therapy?
NeuroStar Advanced Therapy is a non-invasive treatment for depression that has shown to help patients when traditional medications have failed.
How many patients has NeuroStar treated?
As of now, NeuroStar has treated over 88,533 patients, demonstrating its impact in the field of mental health.
What are the goals of the neurohealth initiative?
Neuronetics aims to treat 166,240 people and save 3,325 lives through its innovative NeuroStar TMS treatment over the next five years.
How can I learn more about NeuroStar's achievements?
For detailed stories and information, the NeuroStar Voices Portal is a great resource showcasing diverse experiences from individuals impacted by the therapy.
What should I do if I or someone I know is struggling with depression?
It’s essential to reach out for help. Consider discussing treatment options with a healthcare provider and exploring services like NeuroStar Advanced Therapy.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Leinco Technologies Inc. Expands Portfolio with QED Biosciences
- Jamie Foxx Brings Humor to BetMGM's 2024 Football Campaign
- Wipfli Unveils 2024 Annual Report Detailing Growth and Innovation
- Exdion Insurance Unveils CSRdigit: Revolutionizing E&O Protection
- Sippable Delight: Baileys Cinnamon Churros Cream Liqueur
- Investing Insights: Nvidia Versus Arm Holdings in AI Sector
- Agmatix Unveils RegenIQ: Revolutionizing Regenerative Agriculture
- BoomerangFX Expands Innovative Solutions in Asia and Latin America
- Trethom AS Reduces Major Shareholding in Vow ASA Below 5%
- Supermicro Addresses Concerns Over Annual Report Filing
- Bloomberg CityLab 2024: Global Mayors Gather in Mexico City
- Cork Packaging Market Expected to Hit USD 2.7 Billion Growth
- MICE Industry Expected to Reach $1,337 Billion by 2033
- Packaging Automation Market Growth Driven by E-commerce Boom
- CapexMD Welcomes Alex Shire as New CEO in Exciting Shift
- Tiny Traveler Unveils Advanced AI Baby Monitor for Parents
- Ethical AI Transformation: The P&C Insurance Industry's Role
- HomeSafe Alliance Achieves Milestone Of 100 Military Moves
- Starlight Children's Foundation Celebrates Childhood Cancer Month
- Innovative Wireless Charging Technology Utilizing RF Signals
- Aker ASA Finalizes Aker BioMarine Feed Ingredients Deal
- Fuel for a Cause: Peninsula Bridge Partners with Shell and Loop
- Concord Acquisition Corp II Considers Nasdaq Listing Following Delisting
- IDBS Celebrates Renewal of ISO 9001 and ISO 27001 Certifications
- Exploring the Event Logistics Market Growth to USD 87.8 Billion
Recent Articles
- Autonomous Cars Forecast: Growth to USD 43.44 Billion By 2032
- Bloomberg CityLab 2024: Global Mayors Gather in Mexico City
- MICE Industry Expected to Reach $1,337 Billion by 2033
- Opus Technologies Introduces Paysemble™ for Payment Solutions
- Blue Federal Credit Union Achieves Prestigious Awards in 2024
- Assisted Living Locators' Inspiring Initiative for Alzheimer's Month
- Cambridge Launches Family Business Leadership Programme in 2024
- The Surging Mixed Reality Market: Predicted to Hit USD 76.91 Billion
- IR Spectroscopy Market Growth Predictions Highlighted by R&D
- Roper Technologies to Showcase Innovations at GS Conference
- Coating Additives Market Anticipates Expansive Growth Ahead
- DriveItAway Partners with AllShifts to Support Nurses' Mobility
- DiaCarta Advances MPOX Testing with FDA-EUA-Approved Kits
- Moody's Positive Outlook for Global Reinsurers Highlights Trends
- Ecopetrol S.A. Announces Management Changes and New Roles
- Innovative Insights from Cold Spring Harbor Laboratory's Research
- Gain Therapeutics Heads to H.C. Wainwright Investment Conference
- Troilus Gold Reports Encouraging Drill Results from West Rim Zone
- Bionomics to Present at 26th Annual Global Investment Conference
- PenFed Foundation Supports COMMIT Foundation's Transition Workshops
- JinkoSolar Provides Over 1,000 Solar Modules for Relief
- HSG Laser Celebrates Four Years of Innovation and Growth
- Calliditas Therapeutics' Strategic Response to Asahi Kasei's Move
- Color Star Welcomes Ren Pelosi as New Vice President
- Orthofix Medical Inc. Faces Class Action: Important Investor Update